Giuseppe
Emeritus
[Source: Antimicrobial Agents and Chemotherapy, full text: (LINK). Abstract, edited.]
-------
Neisseria gonorrhoeae strain with high-level resistance to spectinomycin due to a novel resistance mechanism (mutated ribosomal protein S5) verified in Norway
Magnus Unemo 1,*, Daniel Golparian 1, Vegard Skogen 2,3, Anne Olaug Olsen 4,5, Harald Moi 4,5, Gaute Syversen 6 and Stig Ove Hjelmevoll 7
Author Affiliations: <SUP>1</SUP>WHO Collaborating Centre for Gonorrhoea and other STIs, Swedish Reference Laboratory for Pathogenic Neisseria, Department of Laboratory Medicine, Microbiology, ?rebro University Hospital, ?rebro, Sweden; <SUP>2</SUP>Department of Infectious Diseases, University Hospital of North Norway, Troms?, Norway; <SUP>3</SUP>Institute of Clinical Medicine, University of Troms?, Troms?, Norway; <SUP>4</SUP>Olafiaklinikken, Oslo University Hospital, Oslo, Norway; <SUP>5</SUP>University of Oslo, Institute of Clinical Medicine, Oslo, Norway; <SUP>6</SUP>Department of Microbiology, Oslo University Hospital, Oslo, Norway; <SUP>7</SUP>Department of Microbiology and Infection Control, University Hospital of North Norway, Troms?, Norway
ABSTRACT
Gonorrhea may become untreatable and new treatment options are essential. Verified resistance to spectinomycin is exceedingly rare. However, we describe a high-level spectinomycin-resistant (MIC>1024 μg/ml) Neisseria gonorrhoeae strain from Norway with a novel resistance mechanism. The resistance determinant was a deletion of codon 27 and a K28E alteration in the ribosomal protein 5S. The traditional spectinomycin resistance gene (16S rRNA) was wild type. Despite this exceedingly rare finding, spectinomycin available for treatment of ceftriaxone-resistant urogenital gonorrhea would be very valuable.
FOOTNOTES
*Corresponding author. Mailing address: WHO Collaborating Centre for Gonorrhoea and other STIs, Department of Laboratory Medicine, Microbiology, ?rebro University Hospital, SE-701 85 ?rebro, Sweden. Phone: +46 (19) 602 1534. Fax: +46 (19) 127 416. E-mail: magnus.unemo@orebroll.se.
Copyright ? 2012, American Society for Microbiology. All Rights Reserved.
-Magnus Unemo 1,*, Daniel Golparian 1, Vegard Skogen 2,3, Anne Olaug Olsen 4,5, Harald Moi 4,5, Gaute Syversen 6 and Stig Ove Hjelmevoll 7
Author Affiliations: <SUP>1</SUP>WHO Collaborating Centre for Gonorrhoea and other STIs, Swedish Reference Laboratory for Pathogenic Neisseria, Department of Laboratory Medicine, Microbiology, ?rebro University Hospital, ?rebro, Sweden; <SUP>2</SUP>Department of Infectious Diseases, University Hospital of North Norway, Troms?, Norway; <SUP>3</SUP>Institute of Clinical Medicine, University of Troms?, Troms?, Norway; <SUP>4</SUP>Olafiaklinikken, Oslo University Hospital, Oslo, Norway; <SUP>5</SUP>University of Oslo, Institute of Clinical Medicine, Oslo, Norway; <SUP>6</SUP>Department of Microbiology, Oslo University Hospital, Oslo, Norway; <SUP>7</SUP>Department of Microbiology and Infection Control, University Hospital of North Norway, Troms?, Norway
ABSTRACT
Gonorrhea may become untreatable and new treatment options are essential. Verified resistance to spectinomycin is exceedingly rare. However, we describe a high-level spectinomycin-resistant (MIC>1024 μg/ml) Neisseria gonorrhoeae strain from Norway with a novel resistance mechanism. The resistance determinant was a deletion of codon 27 and a K28E alteration in the ribosomal protein 5S. The traditional spectinomycin resistance gene (16S rRNA) was wild type. Despite this exceedingly rare finding, spectinomycin available for treatment of ceftriaxone-resistant urogenital gonorrhea would be very valuable.
FOOTNOTES
*Corresponding author. Mailing address: WHO Collaborating Centre for Gonorrhoea and other STIs, Department of Laboratory Medicine, Microbiology, ?rebro University Hospital, SE-701 85 ?rebro, Sweden. Phone: +46 (19) 602 1534. Fax: +46 (19) 127 416. E-mail: magnus.unemo@orebroll.se.
Copyright ? 2012, American Society for Microbiology. All Rights Reserved.
-------